PharmaEngine (4162) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.011x

Based on the latest financial reports, PharmaEngine (4162) has a cash flow conversion efficiency ratio of 0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$53.01 Million ≈ $1.67 Million USD) by net assets (NT$4.79 Billion ≈ $151.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PharmaEngine balance sheet quality to measure how much of total assets are equity-financed.

PharmaEngine - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how PharmaEngine's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 4162 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

PharmaEngine Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of PharmaEngine ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Gansu Huangtai Wine-marketing Industry Co. Ltd. SHE:000995	0.033x
Anhui Sentai WPC Group Share Co. Ltd. SHE:301429	N/A
MFS Intermediate Income Trust NYSE:MIN	0.046x
Silkroad Visual Technology Co Ltd SHE:300556	0.279x
Computer Direct TA:CMDR	0.094x
Shanghai Challenge Textile Co Ltd SHE:002486	0.068x
Changzhou Tiansheng New Materials Co Ltd SHE:300169	0.028x
Leonteq AG SW:LEON	0.774x

Annual Cash Flow Conversion Efficiency for PharmaEngine (2009–2024)

The table below shows the annual cash flow conversion efficiency of PharmaEngine from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see PharmaEngine market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$5.40 Billion ≈ $170.12 Million	NT$456.73 Million ≈ $14.39 Million	0.085x	+27.15%
2023-12-31	NT$3.86 Billion ≈ $121.70 Million	NT$256.97 Million ≈ $8.10 Million	0.067x	+27.51%
2022-12-31	NT$3.87 Billion ≈ $121.99 Million	NT$202.01 Million ≈ $6.36 Million	0.052x	-77.90%
2021-12-31	NT$3.94 Billion ≈ $124.09 Million	NT$929.67 Million ≈ $29.29 Million	0.236x	+1361.78%
2020-12-31	NT$4.01 Billion ≈ $126.37 Million	NT$64.77 Million ≈ $2.04 Million	0.016x	+249.80%
2019-12-31	NT$3.48 Billion ≈ $109.73 Million	NT$16.08 Million ≈ $506.55K	0.005x	-97.71%
2018-12-31	NT$3.69 Billion ≈ $116.38 Million	NT$745.23 Million ≈ $23.48 Million	0.202x	+332.53%
2017-12-31	NT$3.91 Billion ≈ $123.22 Million	NT$-339.30 Million ≈ $-10.69 Million	-0.087x	-137.86%
2016-12-31	NT$3.80 Billion ≈ $119.68 Million	NT$870.38 Million ≈ $27.42 Million	0.229x	+61.57%
2015-12-31	NT$3.16 Billion ≈ $99.53 Million	NT$447.99 Million ≈ $14.11 Million	0.142x	+216.59%
2014-12-31	NT$2.93 Billion ≈ $92.20 Million	NT$131.09 Million ≈ $4.13 Million	0.045x	+357.03%
2013-12-31	NT$2.72 Billion ≈ $85.63 Million	NT$-47.37 Million ≈ $-1.49 Million	-0.017x	-141.46%
2012-12-31	NT$1.63 Billion ≈ $51.45 Million	NT$68.64 Million ≈ $2.16 Million	0.042x	-90.56%
2011-12-31	NT$618.48 Million ≈ $19.49 Million	NT$275.49 Million ≈ $8.68 Million	0.445x	+163.34%
2010-12-31	NT$81.42 Million ≈ $2.57 Million	NT$-57.26 Million ≈ $-1.80 Million	-0.703x	+91.23%
2009-12-31	NT$11.29 Million ≈ $355.76K	NT$-90.54 Million ≈ $-2.85 Million	-8.018x	--

About PharmaEngine

TWO:4162 Taiwan Biotechnology

Market Cap

$274.07 Million

NT$8.70 Billion TWD

Market Cap Rank

#15135 Global

#643 in Taiwan

Share Price

NT$61.40

Change (1 day)

-0.16%

52-Week Range

NT$53.00 - NT$79.70

All Time High

NT$178.54